Cancer Research

Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.

Cancer Research Products Areas

Products for Cancer Research - Page 108

Cat.No. Product Name Information/Activity
BCC6828 Palmitoylethanolamide Impulsin (AM 3112) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
BCC2265 WY-14643 (Pirinixic Acid) Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
BCC7017 MK 886 MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
BCC2267 GW0742 GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
BCC2268 GW501516 GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM.
BCC1573 FH535 FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
BCC7688 GSK 0660 GSK0660 is a potent antagonist of PPARβ and PPARδ, with IC50s of 155 nM for both isoforms.
BCC2263 GSK3787 GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
BCC7014 Ciglitazone 74772-77-3
BCC7268 nTZDpa 118414-59-8